In support of this, heart failure therapies such has cardiac resynchronisation therapy used to treat refractory chronic heart failure were shown to increase plasma apelin suggesting that increased apelin levels are associated with improved therapeutic benefit54. This evidence concerns the gene APLN and heart failure.